Shanghai Junshi Biosciences Co., Ltd.

Research Shanghai Junshi Biosciences Co., Ltd. (1877.HK) on Bullrun: market cap HKD 16.73B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker1877.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 16.73B
Financial periodFY2025
RevenueCNY 2.50B
Revenue growth28.2%
Net income-CNY 840.91M
Free cash flow-CNY 1.28B
Gross margin79.1%

Valuation Snapshot

latest market cap is HKD 16.73B.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 2.50B	-CNY 840.91M	-CNY 1.28B	79.1%	-0.84	CNY 2.59B	CNY 4.14B	CNY 6.05B
FY2024	CNY 1.95B	-CNY 1.28B	-CNY 2.13B	74.4%	-1.3	CNY 2.49B	CNY 2.93B	CNY 5.88B
FY2023	CNY 1.50B	-CNY 2.28B	-CNY 2.85B	55.6%	-2.32	CNY 3.78B	CNY 1.79B	CNY 7.17B
FY2022	CNY 1.45B	-CNY 2.39B	-CNY 2.17B	63.8%	-2.6	CNY 6.00B	CNY 1.32B	CNY 9.50B

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 16.73B	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)

Frequently asked questions

What is Shanghai Junshi Biosciences Co., Ltd.'s market cap?

Shanghai Junshi Biosciences Co., Ltd.'s market capitalization is HKD 16.73B.

What does Shanghai Junshi Biosciences Co., Ltd. do?

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.